查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1772254

美國分子生物學酵素、試劑和套件市場：市場規模、佔有率、趨勢分析（按產品、應用、最終用途和地區）、細分市場預測（2025-2033）

U.S. Molecular Biology Enzymes, Reagents And Kits Market Size, Share & Trends Analysis Report By Product (Kit and Reagents, Enzymes), By Application (Cloning, NGS, PCR), By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 137 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

預計 2024 年美國分子生物學酶、試劑和套件市場價值將達到 59.5 億美元，預計 2025 年至 2033 年的複合年成長率為 9.65%。

根據美國疾病管制與預防中心（CDC）統計，披衣菌感染、淋病、梅毒等性傳染病在過去十年中呈現穩定上升趨勢，近年來報告病例已超過250萬例。分子技術在研究、診斷和治療的應用不斷擴大。

根據美國癌症協會統計，預計到 2024 年，美國將診斷出超過 200 萬例新癌症病例（不包括泌尿系統癌、基底細胞癌和鱗狀細胞皮膚癌以及非侵入性原位癌）。這種日益加重的疾病負擔預計將維持美國在市場上的領先地位。

2024年11月，加州公共衛生部（CDPH）發現了美國首例經實驗室確診的I型痘苗病毒（mpox）病例。此病例確診於一名近期曾前往疫區的患者。 PCR檢測鑑定出一種非天花正痘病毒，因而確診為I型痘苗病毒。 I型痘苗病毒的出現凸顯了快速精準分子診斷的需求，並促使人們投資於下一代PCR和定序技術。

該市場涵蓋廣泛的產品，包括聚合酵素、連接酶、核酸酶、緩衝液以及用於PCR、qPCR、RT-PCR、克隆、定序和基因表現分析等過程的專用試劑組。此外，腸病毒也會感染5歲以下兒童，其中約41%的感染兒童需要吸氧治療。此外，根據美國國家醫學圖書館2021年5月發表的一篇論文，美國每年約有40%的人口受到病菌感染的影響。

預計政府以核准和資金形式提供的支持將在預測期內推動市場成長。例如，2022年5月，雅培的Alinity m STI檢測試劑盒獲得美國食品藥物管理局（FDA）核准，該試劑盒可識別和檢測性傳播感染（STI）。此外，2020年，美國公共衛生研究院（ASPR）的生物醫學高級研究與發展管理局（BRI）和美國國立衛生研究院（NIH）的國家過敏和傳染病研究所聯合主辦了抗菌素抗藥性診斷挑戰賽，Visby Medical的快速PCR檢測試劑盒獲得了1900萬美元的聯邦資助。

此外，2022年9月，RedBud Medicine在A輪融資中籌集了1,000萬美元。聯邦政府的資金也將有助於提升地方和州檢測實驗室的能力，以滿足日益成長的需求。同樣，2023年6月，Accelerate Diagnostics接受2400萬美元融資，用於加速其Wave平台和新型快速檢測的開發。由於感染疾病的多樣性和病原體的抗藥性，感染疾病的分子診斷檢測菜單不能一成不變或膚淺。

此外，美國市場受到美國主要企業的推動，例如 Promega Corporation 和 Thermo Fisher Scientific，它們提供各種用於診斷的經濟高效的高品質酵素。這些公司提供的酵素可用於生物感測器、糖尿病儀、照護現場設備以及肝臟、心血管、腎臟和其他疾病的體外診斷。 2024 年 9 月，Promega 推出了一種新的酵素變體，可減少法醫學DNA 分析中的卡頓現象，凸顯了其聚合酵素套件的創新。同時，受 PCR 系統升級和高通量實驗室的引入推動，qPCR 和 RT-PCR套件依然保持強勁。此外，2021 年 2 月，安捷倫科技推出了安捷倫 Dako SARS-CoV-2 IgG酵素結合免疫吸附測定套件。此套件可檢測人類血清或血漿中的 SARS-CoV-2 IgG 抗體。

診斷檢測中使用的主要試劑包括螢光標籤、清洗緩衝液、特異性抗體、免疫化學檢查以及PCR檢測的dNTP和引子混合物等必需化學物質。在分子診斷領域，螢光標記的核苷酸和引子被廣泛使用，尤其是在雅培、Illumina和羅氏診斷等行業巨頭的推動下。

COVID-19 相關試劑的監管核准也推動了市場發展。美國FDA 於 2021 年 3 月向 BioFire 呼吸道檢測板 2.1 頒發了 510(k) 許可，使其能夠檢測包括 COVID-19 在內的多種呼吸道感染疾病。同樣，2020 年 4 月，Ortho Clinical Diagnostics 的 VITROS 免疫診斷抗 SARS-CoV-2 總試劑包和校準器獲得了緊急使用授權 (EUA)，這些試劑包和校準器可在 VITROS 診斷系統上運行。此類核准使醫護人員能夠更好地管理和預防 COVID-19，即使在疫情初期出現暫時供不應求的情況下也是如此。這些供不應求最終透過政府干涉、供應鏈恢復和替代產品的推出得到緩解。

目錄

第1章 分析方法與範圍

第2章執行摘要

3. 分子生物學酶、試劑和套件市場：促進因素、趨勢和範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 分子生物學酵素、試劑和套件市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

第4章分子生物學酵素、試劑和套件市場：按產品進行的估計和趨勢分析

  • 各產品市場佔有率（2024 年及 2033 年）
  • 細分儀表板
  • 全球分子生物學酵素、試劑和套件市場（按產品）展望
  • 市場規模預測與趨勢分析（2021-2033）
    • 套件和試劑
    • 酵素

第5章分子生物學酶、試劑和套件市場：按應用的估計和趨勢分析

  • 按應用分類的市場佔有率（2024 年和 2033 年）
  • 細分儀表板
  • 全球分子生物學酵素、試劑和套件市場展望（按應用）
  • 市場規模預測與趨勢分析（2021-2033）
    • 複製
    • 定序
    • PCR
    • 表觀遺傳學
    • 基因分型
    • RCA/MDA
    • RNA治療學
    • 轉錄組學
    • 蛋白質體學
    • 液態生物檢體
    • 其他用途

第6章分子生物學酶、試劑和套件市場：按最終用途的估計和趨勢分析

  • 按最終用途分類的市場佔有率（2024 年和 2033 年）
  • 細分儀表板
  • 全球分子生物學酶、試劑和套件市場展望（按最終用途）
  • 市場規模預測與趨勢分析（2021-2033）
    • 製藥和生物技術
    • 學術研究
    • 醫院/診斷
    • 其他

第7章 競爭態勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 公司熱圖分析
  • 公司簡介
    • Illumina, Inc.
    • Thermo Fisher Scientific, Inc.
    • Agilent Technologies, Inc.
    • QIAGEN
    • Promega Corporation
    • New England Biolabs
    • Merck KGaA
    • F. Hoffmann-La Roche Ltd.
    • Bio-Rad Laboratories, Inc.
    • Takara Bio, Inc.
    • LGC Limited
Product Code: GVR-4-68040-645-5

Market Size & Trends:

The U.S. molecular biology enzymes, reagents and kits market size was estimated at USD 5.95 billion in 2024 and is projected to grow at a CAGR of 9.65% from 2025 to 2033. The market is driven by growing burden of chronic diseases and infectious diseases such as sexually transmitted diseases (STDs) across the U.S. According to the Centers for Disease Control and Prevention (CDC), STDs such as chlamydia, gonorrhea, and syphilis have been increasing steadily over the past decade, with over 2.5 million cases reported in recent years. The expanding application of molecular technologies in research, diagnostics, and therapeutics.

According to the American Cancer Society, over 2 million new cancer cases are projected to be diagnosed in the U.S. in 2024, excluding basal and squamous cell skin cancers and noninvasive carcinoma in situ, except for urinary bladder cases. This rising disease burden is expected to sustain the country's leadership in the market.

In November 2024, the California Department of Public Health (CDPH) confirmed the first case of clade I mpox in the U.S. through laboratory testing. The diagnosis was made in a patient who had recently traveled to an outbreak region. PCR testing identified non-variola orthopoxvirus and confirmed clade I mpox, with further analysis conducted by the CDC. The emergence of clade I mpox underscores the necessity for rapid and precise molecular diagnostics, fostering investment in next-generation PCR and sequencing technologies.

This market encompasses a broad range of products, including polymerases, ligases, nucleases, buffers, and specialized reagent kits designed for processes such as PCR, qPCR, RT-PCR, cloning, sequencing, and gene expression analysis. Furthermore, enterovirus also majorly affects the population with ages less than 5 years, of which around 41% of the infected toddlers require supplemental oxygen. In addition, according to the article published by the National Library of Medicine in May 2021, around 40 % of the U.S. population in the U.S. is affected by H. pylori infection every year.

The presence of government support in the form of approvals and funding is anticipated to fuel the market growth over the forecast period. For instance, in May 2022, Abbot received approval for its Alinity m STI Assay from the U.S. FDA. The test is capable of differentiating and detecting STIs. In addition, in 2020, ASPR's Biomedical Advanced Research and Development Authority and NIH's National Institute of Allergy and Infectious Diseases organized the Antimicrobial Resistance Diagnostic Challenge in which Visby Medical's rapid PCR test won USD 19 million in federal funding.

In addition, in September 2022, Redbud Medicine raised USD 10 million in Series A funding. Federal funding also helps local and state laboratories increase their capacity and allows them to keep up with increasing demand. Similarly, in June 2023, Accelerate Diagnostics, Inc. received USD 24 million to accelerate the development of the Wave platform and novel rapid testing. Molecular diagnostics test menus for infectious diseases cannot afford to be static or superficial due to the diverse nature of infectious diseases and the building resistance of causative agents.

Furthermore, local presence of key players such as Promega Corporation and Thermo Fisher Scientific, which offer cost-effective, high-quality, & a wide range of enzymes to be used in diagnosis, is driving the U.S. market. These companies offer enzymes that can be used in biosensors, diabetes meters, point-of-care devices, and in vitro diagnosis of liver, cardiovascular, renal, and other disorders. Promega introduced a novel enzyme variant in September 2024 that cuts stutter in forensic DNA analysis, highlighting innovation in polymerase kits. Meanwhile, qPCR and RT-PCR kits remain strong, supported by PCR system upgrades and high-throughput lab adoption. In addition, in February 2021, Agilent Technologies Inc. launched the Agilent Dako SARS-CoV-2 IgG enzyme-linked immunosorbent assay kit. It detects IgG antibodies to SARS-CoV-2 in human blood serum or plasma.

Key reagents used in diagnostic assays include fluorescent tags, washing buffers, specific antibodies, and protein biomarkers for immunochemistry tests, along with essential chemicals like dNTP and primer mixes for PCR testing. In molecular diagnostics, fluorescent-labeled nucleotides and primers are frequently utilized, particularly by industry leaders such as Abbott, Illumina, Inc., and Roche Diagnostics.

Regulatory approvals for COVID-19-related reagents have also fueled the market. The U.S. FDA granted 510(k) clearance for the BioFire Respiratory Panel 2.1 in March 2021, enabling the detection of multiple respiratory infections, including COVID-19. Similarly, in April 2020, Ortho Clinical Diagnostics received an Emergency Use Authorization (EUA) for the VITROS Immunodiagnostic Anti-SARS-CoV-2 Total Reagent Pack and Calibrators, which operate on the VITROS diagnostic systems. Such approvals allow healthcare professionals to better manage and prevent COVID-19, even amidst temporary shortages that occurred early in the pandemic. These shortages were eventually mitigated through governmental interventions, restored supply chains, and the launch of alternative products

U.S. Molecular Biology Enzymes, Reagents And Kits Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. molecular biology enzymes, reagents and kits market report based on product, application, and end use

Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Kits & Reagents
  • PCR Kits
  • qPCR Kits
  • RT-PCR Kits
  • Library Preparation Kits
  • Cloning Kits
  • Purification Kits
  • Gene Editing Kits
  • Other Kits
  • Enzymes
  • Polymerases
    • DNA Polymerases
    • High Fidelity DNA Polymerases
    • Pfu DNA Polymerases
    • Phusion DNA Polymerases
    • Hot Start DNA Polymerases
    • Taq DNA Polymerases High Fidelity
    • Others
    • Thermostable DNA Polymerases
    • Standard Taq DNA Polymerases
    • Tth DNA Polymerases
    • Others
    • Strand-displacing DNA Polymerases
    • Bst DNA Polymerases
    • Phi29 DNA Polymerases
    • Others
    • RNA Polymerases
    • T7 RNA Polymerase
    • SP6 RNA Polymerase
    • T3 RNA Polymerase
    • Other RNA Polymerase
  • Reverse Transcriptase (RTs)
    • M-MLV RT
    • AMV RT
    • Thermostable RT
    • Template Switch
    • TGIRT
    • Induro
    • MarathonRT
  • Ligases
    • DNA Ligases
    • T4 DNA Ligases
    • E coli DNA Ligase
    • Taq DNA Ligase
    • Others
    • RNA Ligases
  • Nucleases
    • DNase I
    • RNase A, RNase H
    • Nickases
    • Restriction Nucleases
    • TdTs
  • Endonucleases
    • EndoQ
    • AP Nuclease
  • Kinases
  • Phosphatases
  • CRISPR-associated Enzymes
    • Cas9
    • Cas12a (Cpf1)
    • Cas13
  • Specialty Enzymes
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Cloning
  • Sequencing
  • PCR
  • Epigenetics
  • Genotyping
  • RCA/MDA
  • RNA Therapeutics
  • Transcriptomics
  • Proteomics
  • Liquid Biopsy
  • Other Applications
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharma & Biotech
    • Research
    • Therapeutics/Production
  • Academic & Research
  • Hospital & Diagnostics
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Outlook
    • 2.2.2. Application Outlook
    • 2.2.3. End Use Outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Molecular Biology Enzymes, Reagents And Kits Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Molecular Biology Enzymes, Reagents And Kits Market Analysis Tools
    • 3.3.1. Industry Analysis Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Molecular Biology Enzymes, Reagents And Kits Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Molecular Biology Enzymes, Reagents And Kits Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Kits & Reagents
      • 4.4.1.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.2. PCR Kits
        • 4.4.1.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.3. qPCR Kits
        • 4.4.1.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.4. RT-PCR Kits
        • 4.4.1.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.5. Library Preparation Kits
        • 4.4.1.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.6. Cloning Kits
        • 4.4.1.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.7. Purification Kits
        • 4.4.1.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.8. Gene Editing Kits
        • 4.4.1.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.9. Other Kits
        • 4.4.1.9.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Enzymes
      • 4.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.2. Polymerases
        • 4.4.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.2.2. DNA Polymerases
          • 4.4.2.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.2. High Fidelity DNA Polymerases
            • 4.4.2.2.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.2.2. Pfu DNA Polymerases
      • 4.4.2.2.2.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.2.3. Phusion DNA Polymerases
            • 4.4.2.2.2.2.4. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.2.5. Hot Start DNA Polymerases
            • 4.4.2.2.2.2.6. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.2.7. Taq DNA Polymerases High Fidelity
          • 4.4.2.2.2.3. Thermostable DNA Polymerases
            • 4.4.2.2.2.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.3.2. Standard Taq DNA Polymerases
      • 4.4.2.2.2.3.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.3.3. Tth DNA Polymerases
      • 4.4.2.2.2.3.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.3.4. Others
      • 4.4.2.2.2.3.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.4. Strand-displacing DNA Polymerases
          • 4.4.2.2.2.5. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.6. Bst DNA Polymerases
            • 4.4.2.2.2.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.7. Phi29 DNA Polymerases
            • 4.4.2.2.2.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.8. Others
            • 4.4.2.2.2.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.2.3. RNA Polymerases
          • 4.4.2.2.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.3.2. T7 RNA Polymerase
            • 4.4.2.2.3.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.3.3. SP6 RNA Polymerase
            • 4.4.2.2.3.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.3.4. T3 RNA Polymerase
            • 4.4.2.2.3.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.3.5. Other RNA Polymerase
            • 4.4.2.2.3.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.3. Reverse Transcriptase (RTs)
        • 4.4.2.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.2. M-MLV RT
          • 4.4.2.3.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.3. AMV RT
          • 4.4.2.3.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.4. Thermostable RT
          • 4.4.2.3.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.5. Template Switch
          • 4.4.2.3.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.6. TGIRT
          • 4.4.2.3.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.7. Induro
          • 4.4.2.3.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.8. MarathonRT
          • 4.4.2.3.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.4. Ligases
        • 4.4.2.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.4.2. DNA Ligases
          • 4.4.2.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.4.2.2. T4 DNA Ligases
          • 4.4.2.4.2.3. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.4.2.4. E coli DNA Ligase
          • 4.4.2.4.2.5. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.4.2.6. Taq DNA Ligase
          • 4.4.2.4.2.7. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.4.2.8. Others
          • 4.4.2.4.2.9. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.4.3. RNA Ligases
          • 4.4.2.4.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.5. Nucleases
        • 4.4.2.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.2. DNase I
          • 4.4.2.5.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.3. RNase A, RNase H
          • 4.4.2.5.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.4. Nickases
          • 4.4.2.5.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.5. Restriction Nucleases
          • 4.4.2.5.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.6. TdTs
          • 4.4.2.5.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.6. Endonucleases
        • 4.4.2.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.6.2. EndoQ
          • 4.4.2.6.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.6.3. AP Nuclease
          • 4.4.2.6.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.7. Kinases
        • 4.4.2.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.8. Phosphatases
        • 4.4.2.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.9. CRISPR-associated Enzymes
        • 4.4.2.9.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.9.2. Cas9
          • 4.4.2.9.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.9.3. Cas12a (Cpf1)
          • 4.4.2.9.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.9.4. Cas13
          • 4.4.2.9.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.10. Specialty Enzymes
        • 4.4.2.10.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.11. Others
        • 4.4.2.11.1. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Molecular Biology Enzymes, Reagents And Kits Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Molecular Biology Enzymes, Reagents And Kits Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Cloning
      • 5.4.1.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Sequencing
      • 5.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3. PCR
      • 5.4.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.4. Epigenetics
      • 5.4.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.5. Genotyping
      • 5.4.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.6. RCA/MDA
      • 5.4.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.7. RNA Therapeutics
      • 5.4.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.8. Transcriptomics
      • 5.4.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.9. Proteomics
      • 5.4.9.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.10. Liquid Biopsy
      • 5.4.10.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.11. Other Applications
      • 5.4.11.1. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Molecular Biology Enzymes, Reagents And Kits Market: End use Estimates & Trend Analysis

  • 6.1. End use Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Molecular Biology Enzymes, Reagents And Kits Market by End use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Pharma & Biotech
      • 6.4.1.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.2. Academic & Research
      • 6.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. Hospital & Diagnostics
      • 6.4.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.4. Other
      • 6.4.4.1. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Illumina, Inc.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/Strategic Initiatives
    • 7.4.2. Thermo Fisher Scientific, Inc.
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/Strategic Initiatives
    • 7.4.3. Agilent Technologies, Inc.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/Strategic Initiatives
    • 7.4.4. QIAGEN
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/Strategic Initiatives
    • 7.4.5. Promega Corporation
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/Strategic Initiatives
    • 7.4.6. New England Biolabs
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/Strategic Initiatives
    • 7.4.7. Merck KGaA
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/Strategic Initiatives
    • 7.4.8. F. Hoffmann-La Roche Ltd.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/Strategic Initiatives
    • 7.4.9. Bio-Rad Laboratories, Inc.
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/Strategic Initiatives
    • 7.4.10. Takara Bio, Inc.
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/Strategic Initiatives
    • 7.4.11. LGC Limited
      • 7.4.11.1. Participant's Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Recent Developments/Strategic Initiatives

List of Tables

  • Table 1 List of key distributors and channel partners
  • Table 2 List of key emerging companies'/technology disruptors/innovators
  • Table 3 U.S. Molecular biology enzymes, reagents and kits Market, By Product, 2021 - 2033 (USD Million)
  • Table 4 U.S. Molecular biology enzymes, reagents and kits Market, By Application, 2021 - 2033 (USD Million)
  • Table 5 U.S. Molecular biology enzymes, reagents and kits Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research
  • Fig. 4 Value-chain-based sizing & forecasting
  • Fig. 5 QFD modelling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Market outlook
  • Fig. 9 Segment snapshot-1
  • Fig. 10 Segment snapshot-2
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Market trends & outlook
  • Fig. 13 Porter's five force analysis
  • Fig. 14 PESTEL analysis
  • Fig. 15 U.S. molecular biology enzymes, reagents and kits market: Product outlook key takeaways
  • Fig. 16 U.S. molecular biology enzymes, reagents and kits market: Product movement analysis
  • Fig. 17 Kits & Reagents Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 PCR Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 qPCR Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 RT-PCR Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Library Preparation Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Cloning Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Purification Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Gene Editing Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Other Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Enzymes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 High Fidelity DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Pfu DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Phusion DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Hot Start DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Taq DNA Polymerases High Fidelity Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Thermostable DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Standard Taq DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Tth DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Strand-displacing DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Bst DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Phi29 DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 RNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 T7 RNA Polymerase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 SP6 RNA Polymerase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 T3 RNA Polymerase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Other RNA Polymerase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Reverse Transcriptase (RTs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 M-MLV RT Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 AMV RT Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Thermostable RT Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Ligases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 DNA Ligases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 T4 DNA Ligases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 E. coli DNA Ligase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Taq DNA Ligase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 RNA Ligases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Nucleases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 DNase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 RNase A, RNase H Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Nickases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Restriction Nucleases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 TdTs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Endonucleases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 EndoQ Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 AP Nuclease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Kinases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Phosphatases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 CRISPR-associated Enzymes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Cas9 Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Cas12a (Cpf1) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Cas13 Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Specialty Enzymes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 U.S. molecular biology enzymes, reagents and kits market: Application outlook key takeaways
  • Fig. 77 U.S. molecular biology enzymes, reagents and kits market: Application movement analysis
  • Fig. 78 Cloning - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Sequencing - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 PCR - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 Epigenetics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Genotyping - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 RCA/MDA - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 RNA Therapeutics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Transcriptomics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Proteomics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 Liquid Biopsy - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Other Applications - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 89 U.S. molecular biology enzymes, reagents and kits market: End Use outlook key takeaways
  • Fig. 90 U.S. molecular biology enzymes, reagents and kits market: End Use movement analysis
  • Fig. 91 Pharma & Biotech - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Academic & Research - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 93 Hospital & Diagnostics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Others - Market Estimates and Forecasts, 2021 - 2033 (USD Million)